102
Views
12
CrossRef citations to date
0
Altmetric
Review

Outcome measures for clinical trials in Parkinson’s disease: achievements and shortcomings

&
Pages 985-993 | Published online: 10 Jan 2014

REFERENCES

  • Fahn S, Elton RL. Unified Parkinson's disease rating scale. In: Recent Developments in Parkinson's disease. Fahn S, Marsden CD, Calne DB, Goldstein M (Eds). MacMillan Healthcare, NJ, USA, 153–163 (1987).
  • Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mow Disord. 17, 867–876 (2002).
  • Movement Disorder Society Task Force on Rating Scales for Parkinson's D. The Unified Parkinson's disease Rating Scale (UPDRS): status and recommendations. Mow Disord. 18,738–750 (2003).
  • Bennett DA, Shannon KM, Beckett LA, Goetz CG, Wilson RS. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's disease Rating Scale. Neurology 49,1580–1587 (1997).
  • Duvoisin RC. The evaluation of extrapyramidal disease. In: Monoamines Noyaux Cris Centraux et Syndrome de Parkinson. Ajuriaguerra J, Gauthier G (Eds). Georg & Cie, Geneva, Switzerland, 313–325 (1971).
  • Webster DD. Clinical analysis of the disability in Parkinson's disease. Mod. Treatment 5,257–282 (1968).
  • Mitchell SL, Harper DW, Lau A, Bhalla R. Patterns of outcome measurement in Parkinson's disease clinical trials. Neuroepidemiology19,100–108 (2000).
  • Aaronson NK. Quantitative issues in health-related quality of life assessment. Health Pol. 10,217–230 (1988).
  • Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neural. 245, S10 —S14 (1998).
  • de Boer AG, Wijker W, Speelman JD, de Haes JC. Quality of life in patients with Parkinson's disease: development of a questionnaire. J. Neural. Neurosurg. Psychiatry 61,70-74 (1996). itCalne SM, Mak E, Hall J et al. Validating a quality-of-life scale in caregivers of patients with Parkinson's disease: Parkinson's Impact Scale (PIMS). Advances Neural. 91, 115–122 (2003).
  • Welsh M, McDermott MP, Holloway RG et aL Development and testing of the Parkinson's disease quality of life scale. Mov. Disord. 18,637–645 (2003).
  • Marinus J, Ramaker C, van Hilten JJ, Stiggelbout AM. Health-related quality of life in Parkinson's disease: a systematic review of disease specific instruments. J NeuroL Neurosurg. Psychiatry 72,241–248 (2002).
  • de Bruin AF, de Witte LP, Stevens F, Diederiks JE Sickness Impact Profile: the state of the art of a generic functional status measure. Soc. Sci. Med. 35,1003–1014 (1992).
  • McHarney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 31,247–263 (1993).
  • Hunt SM, McEwen J, McKenna SE Measuring health status: a new tool for clinicians and epidemiologists. J. R. Coll. Gem Prac. 35,185–188 (1985).
  • EuroQ01 G. EuroQ01: a new facility for the measurement of health related quality of life. Health PoL 12,199–208 (1990).
  • Kaplan RM, Bush JVV, Berry CC. Health status: types of validity and the index of well-being. Health Serv. Res. 11,478-507 (1976).
  • Kaplan RM, Anderson JE A general health policy model: update and applications. Health Serv. Res. 23, 203–235 (1988).
  • Feeny D, Furlong W, Boyle M, Torrance GW Multi-attribute health status classification systems. Health Utilities Index. PharmacoEconomics 7,490–502 (1995).
  • Brefel-Courbon C, Desboeuf K, Thalamas C et al. Clinical and economic analysis of spa therapy in Parkinson's disease. Mov Disord. 18,578–584 (2003).
  • Hauser RA, Molho E, Shale H, Pedder S, Dorflinger EE. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De novo Study Group. Mov. Disord. 13,643–647 (1998).
  • The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet353, 2041–2042 (1999).
  • Hutton JT, Metman LV, Chase TN et al. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov. Disord. 16,459-463 (2001).
  • Suchowersky O, Bailey P, Pourcher E, Bulger L, Facciponte G. Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. Clin. NeuropharmacoL 24,214–220 (2001).
  • Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F, The 043 Study G. A 6-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Trans. 109,489-502 (2002).
  • Freed CR, Greene PE, Breeze RE et aL Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N EngL J. Med. 344,710–719 (2001).
  • Clarke CE, Cooper JA, Holdich TA, Group TS. A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations. Clin. NeuropharmacoL 24, 133–138 (2001).
  • Carr JA, Honey CR, Sinden M, Phillips AG, Martzke JS. A waitlist control-group study of cognitive, mood, and quality of life outcome after posteroventral pallidotomy in Parkinson's disease. J. Neurosurgery 99, 78–88 (2003).
  • Fenelon G, Gimenez-Roldan S, MontastrucTh et al Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J. Neural 7ians. 110,239-251 (2003).
  • Wade DT, Gage H, Owen C, Trend P, Grossmith C, Kaye J. Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study. J. NeuroL Neurosurg. Psychiatry 74,158–162 (2003).
  • Adler CH, Singer C, O'Brien C et aL Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch. NeuroL 55,1089–1095 (1998).
  • Baas H, Beiske AG, Ghika J et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the wearing off phenomenon and levodopa requirements in fluctuating parkinsonian patients. Neurology 50, S46—S53 (1998).
  • Waters CH, Kurth M, Bailey P et aL Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Study Group. Neurology 50, S39—S45 (1998).
  • Koller W, Lees A, Doder M, Hely M, Tolcapone/Pergolide Study G. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov. Disord. 16,858–866 (2001).
  • Jarman B, Hurwitz B, Cook A, Bajekal M, Lee A. Effects of community based nurses specialising in Parkinson's disease on health outcome and costs: randomised controlled trial. Br. Med. J. 324,1072-1075 (2002).
  • Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopailevodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology53, 1012–1019 (1999).
  • de Bie RM, de Haan RJ, Nijssen PC et aL Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial. Lancet 354,1665–1669 (1999).
  • Pacchetti C, Mancini F, Aglieri R, Fundaro C, Martignoni E, Nappi G. Active music therapy in Parkinson's disease: an integrative method for motor and emotional rehabilitation. Psycho. Med. 62, 386–393 (2000).
  • Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin. NeuropharmacoL 23,34–44 (2000).
  • Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease: the TEMPO Study. Arch. NeuroL 59, 1937–1943 (2002).
  • Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA 284,1931–1938 (2000).
  • Scott DL, Garrood T. Quality of life measures: use and abuse. Best Prac. Res. Clin. RheumatoL 14,663–687 (2000).
  • Marras C, Lang AE. Measuring motor complications in clinical trials for early Parkinson's disease. J. NeuroL Neurosurg. Psychiatry74,143–146 (2003).
  • Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann. NeuroL 39,37–45 (1996).
  • Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose-ranging study. JAMA 278,125–130 (1997).
  • Rascal O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A 5-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl. J Med. 342, 1484–1491 (2000).
  • Cedarbaum JM, Gandy SE, McDowell FH. Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 41,622–629 (1991).
  • Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopailevodopa in PD. A 5-year randomized multicenter study. Neurology 53,1012–1019 (1999).
  • Ahlskog JE, Muenter M. The frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16, 448–458 (2001).
  • Rascal O, De Deyn PP, Watts RL, Korczyn A, Lang AE. Reduced dyskinesias with ropinirole in a naturalistic 8.5 year follow-up of patients with early parkinson's disease who had initially received ropinirole or L-dopa. Mov. Disord. 19, S253 (2004).
  • Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch. Neural. 61,1044-1053 (2004).
  • Comparisons of therapeutic effects of levodopa, levodopa, and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's disease Research Group in the United Kingdom. Br. Med. J 307, 469–472 (1993).
  • Melamed E, Olanow CW, Nutt JG, Lang AE. Dyskinesias assessment workshop: reports from the working groups. Mov. Disord. 14,69–73 (1999).
  • Shults CW, Oakes D, Kieburtz K et al. Effects of coenzyme Q10 in early Parkinson's disease: evidence of slowing of the functional decline. Arch. Neurol. 59, 1541–1550 (2002).
  • Larsen JP, Boas J, Erdal JE. Does selegiline modify the progression of early Parkinson's disease? Results from a 5-year study. The Norwegian-Danish Study Group. Eur. Neural. 6,539-547 (1999).
  • Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease. Arch. Neural. 61,561–566 (2004).
  • •Provides an example of delayed start methodology.
  • Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Eng. J. Med. 321, 1364–1371 (1989).
  • Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann. Neural. 40,99–107 (1996).
  • Olanow CW, Hauser RA, Gauger L et aL The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neural. 38,771–777 (1995).
  • Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann. Neural. 44, S160—S166 (1998).
  • The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl. J Med. 328, 176–183 (1993).
  • Parkinson Study Group. Anonymous. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch. Neural. 52,237–245 (1995).
  • Parkinson Study Group. Does levodopa slow or hasten the progression of Parkinson's disease: the results of the ELLDOPA study. N Eng. J. Med. (2004) (In Press).
  • •Provides an example of challenges interpreting neuroprotective trials with respect to counfounding by symptomatic effects and biomarker assessment of disease progression.
  • Seibyl JP, Marek KL, Quinlan D et al. Decreased single-photon emission computed tomographic 11231113-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol. 38, 589–598 (1995).
  • Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with 118F1dopa PET. J. Neurol, Neurosurg. Psychiatry64,314–319 (1998).
  • Brooks DJ, Frey KA, Marek KL etal. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp. Neurol. 184, S68—S79 (2003).
  • Marek K. Pramipexole versus levodopa: effects on Parkinson's disease progression assessed by dopamine transporter imaging. Neurology 58, A82—A82 (2002).
  • Whone AJ, Remy P, Davis MR et aL The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared withl-dopa. Neurology 58, A82—A82 (2002).
  • Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 3,309–316 (2004).
  • Sair HI, Doraiswamy PM, Petrella JR. In vivo amyloid imaging in Alzheimer's disease. Neuroradiology 46, 93–104 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.